Who is sponsoring NCT07264634?

NCT07264634 is sponsored by Ascendis Pharma A/S.

What condition does NCT07264634 study?

NCT07264634 studies Hypoparathyroidism.

What drugs are being tested in NCT07264634?

Interventions: Palopegteriparatide.

What is the status of NCT07264634?

NCT07264634 is currently RECRUITING.

Last reviewed 2026-04-15 · How we verify

A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide)

NCT07264634 RECRUITING

This is an observational, opportunistic lactation study to be conducted in lactating female participants who are currently receiving therapeutic doses of YORVIPATH as part of their usual care and who have chosen to breastfeed their infant(s). The potential transfer of palopegteriparatide into breast milk will be assessed.

Details

Lead sponsor	Ascendis Pharma A/S
Status	RECRUITING
Enrolment	10
Start date	2026-03-19
Completion	2028-01

Conditions

Hypoparathyroidism

Interventions

Palopegteriparatide

Primary outcomes

To evaluate the transfer of palopegteriparatide into human breast milk of lactating female participants who are breastfeeding while being treated with YORVIPATH — 6 days

Countries

United States